Dr. Martens PLC
06 August 2026
6 August 2026
Dr. Martens plc
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
Dr. Martens plc ('Dr. Martens' or 'the Company') is pleased to announce the appointment of Alia Gogi as an Independent Non-Executive Director of the Company with effect from 1 September 2026.
Alia has significant international retail and commercial experience, with a strong track record across consumer brands, omnichannel growth and Asian markets. She was most recently President, Asia at Sephora, part of LVMH, where she oversaw operations across ten markets. She previously held a number of senior leadership roles at Sephora, including Managing Director for Southeast Asia and Senior Vice President of Merchandising for Asia and Greater China. Earlier in her career, Alia held senior commercial roles at A.S. Watson Group and in brand and category management at Nestlé and J Sainsbury. Alia is currently an Independent Director of global beauty company, Coty Inc.
Upon joining the Board, Alia will also become a member of the Audit and Risk, Remuneration and Nomination Committees.
Paul Mason, Chairman, said: 'The Board is pleased to welcome Alia to Dr. Martens. As we continue to execute our consumer-first strategy, her strong consumer and product focus, together with her international perspective and experience of omnichannel growth, will bring valuable insight as we continue to develop and scale the Dr. Martens brand globally'.
NOTES
1. This announcement is made pursuant to UK Listing Rule 6.4.6R.
2. The Company confirms that there is no further information that is required to be disclosed pursuant to UK Listing Rule 6.4.8R.
Enquiries
Investors and analysts
Louise Durey, Investor Relations and Corporate Communications Senior Manager
Press enquiries:
Rob Greening / Ludo Baynham-Herd
drmartens@client.sodali.com
+44 207 250 1446
About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.
Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people. The company continues to honour the brand's heritage through its 'Made in England' footwear, manufactured at its original Northamptonshire factory, while meeting global demand from multiple high-quality production sites across Asia. All our products are made with an unwavering commitment to craft, combined with innovative techniques.
A brand built to put a bounce in the step of those who stand out from the crowd, Dr. Martens is available through Direct-to-Consumer (Retail and Ecommerce) and Wholesale channels. The brand's collections range from its Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976 Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz, and Lowell. The lineup also includes an extensive range of sandals, a dedicated Kids collection, and a curated selection of bags, small leather goods, and accessories.
Every Dr. Martens product reflects craftsmanship, heritage, timeless style, comfort, and versatility. Having transcended generations, the brand stays as relevant today as it was at its inception. Its signature yellow welt stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops remain iconic symbols recognised around the world.
Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock Exchange and is a constituent of the FTSE 250 index.
For more information, visit www.drmartens.com or www.drmartensplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.